FDA approval miss leads to Epix job losses
This article was originally published in Clinica
Executive Summary
Epix Pharmaceuticals is to slash its workforce by 50% in January next year, as a result of the disappointing decision by the FDA to hold back approval of the company's Vasovist blood-pool contrast agent.